3 mg DRSP/20 μg EE
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome
Trial Timeline
Aug 1, 2011 → Feb 1, 2015
NCT ID
NCT01360996About 3 mg DRSP/20 μg EE
3 mg DRSP/20 μg EE is a approved stage product being developed by Bayer for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01360996. Target conditions include Polycystic Ovary Syndrome.
What happened to similar drugs?
2 of 13 similar drugs in Polycystic Ovary Syndrome were approved
Approved (2) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01360996 | Approved | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome